ARS Pharmaceuticals(SPRY.US)

Last Updated 19:00:00 ET
longbridge loading

Key facts: ARS neffy approved US/Canada/EU; rev $22.7M, loss $60.6M

TradingView·
US
SPRY
-1.78%
TradingView·
US
SPRY
-1.78%

Sector Update: Healthcare Stocks Softer Friday Afternoon

Fidelity·
US
ALMS
+1.77%
US
DXCM
+2.86%
US
SPRY
-1.78%
Fidelity·
US
ALMS
+1.77%
US
DXCM
+2.86%
US
SPRY
-1.78%

ARS Pharmaceuticals shares are trading lower after the company reported mixed Q1 financial results.

benzinga_article·
US
SPRY
-1.78%
benzinga_article·
US
SPRY
-1.78%

ARS Pharmaceuticals Highlights Strong Neffy Growth and Global Expansion

Tip Ranks·
US
SPRY
-1.78%
Tip Ranks·
US
SPRY
-1.78%

ARS Pharmaceuticals 1Q 2026: Revenue $22.7M, EPS $(0.61) — 10-Q Summary

TradingView·
US
SPRY
-1.78%
TradingView·
US
SPRY
-1.78%

ARS Pharmaceuticals | 8-K: FY2026 Q1 Revenue Beats Estimate at USD 22.68 M

Earnings Watch·
US
SPRY
-1.78%
Earnings Watch·
US
SPRY
-1.78%
© 2026 Longbridge｜Disclaimer